Business Context and Reporting Period
This Form 8-K is a current report filed by Akers Biosciences, Inc. (the "Company") on September 11, 2018, regarding an event that occurred on September 6, 2018. The Company is incorporated in New Jersey and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Mr. Joshua Silverman as a Director of the Company. The appointment was made by the Board of Directors upon the recommendation of the Nominating and Corporate Governance Committee. His term expires at the Company's 2019 Annual Meeting of Stockholders or upon earlier death, disability, resignation, or removal. The Board has not yet determined which committees, if any, Mr. Silverman will serve on.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. There are no reported related party transactions involving Mr. Silverman, nor are there any material plans, contracts, or arrangements to which he is a party resulting from this appointment. The filing explicitly states there is no arrangement or understanding between Mr. Silverman and other persons regarding his selection.
Investor Verification Checklist
- Verify the biographical background of the newly appointed Director, Mr. Joshua Silverman, including his roles at Parkfield Funding LLC, Iroquois Capital Management, and other public companies.
- Confirm the absence of any undisclosed related party transactions or compensatory arrangements associated with the new appointment.
- Monitor future filings for the assignment of Mr. Silverman to specific Board committees.
- Note that this filing does not update the Company's financial status; refer to the most recent 10-K or 10-Q for financial metrics.